Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by kishamaranason Dec 22, 2020 9:21am
89 Views
Post# 32159714

Developing Treatment

Developing Treatment
 
 
According to the Center for Disease and Control and Prevention, approximately 1% of children globally suffer from autism. In the United States only, an estimated figure is given of 1 out of almost 70 births in the country. It is marked as one of the fastest growing developmental disease increasing at a rate of approximately 119% from 2000 to the year 2014
 
Unfortunately, there is a rather large unmet medical need when it comes to ASD .But there is a compound that could potentially revolutionize the treatment of ASD- Psilocybin.
 
Then there's these other companies developing a diversified pipeline with psilocybin-based treatments claiming to target ASD.
 
With this development treatment for ASD patient would you support? Check disclaimer on profile
<< Previous
Bullboard Posts
Next >>